Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNBELIEVABLE: Biogen - The Untold Story

How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

Barchart

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch

MarketBeat

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf

MarketBeat

Are Wall Street Analysts Bullish on Biogen Stock?

Biogen has rallied the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval

Denali Therapeutics (NASDAQ:DNLI) is seeing early commercial interest for its first approved drug, AVLAYAH, following its March 24 accelerated approval for Hunter syndrome, Chief Operating Officer and Chief Financial Officer Alexander Schuth said at a Bank of America Securities conference. Speaking

MarketBeat

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam Meyers, head of the company’s immunology and new disease areas franchise, said at Bank of America’s

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

Genome sequencing is rewriting the history of disease outbreaks – but without social context, it can tell only part of the story

Fingerprinting transformed police investigations by making it possible to place a suspect at a crime scene with physical evidence. Similarly, genome sequencing has changed how disease detectives study outbreaks by allowing them to read a pathogen’s genes as a biological record of where it came from and how it spread.

The Conversation

FDA Extends Review of Eisai, Biogen Alzheimer's Drug

The agency pushed its decision on weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's initial treatment to Aug. 24 after seeking additional information.

International Business Times

Biogen Earnings Preview: What to Expect

Biogen is poised to announce its first-quarter results next week, and analysts predict a marginal drop in the company’s bottom-line figure.

Barchart

Stocks Surge on Signs the US and Iran Seek to End War

The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +2.91%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +2.49%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.43%. June E-mini S&P futures (ESM26 ) rose +2.88%, and June E-mini Nasdaq futures...

Barchart

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

Barchart

Stocks Climb on Hopes for an End to Iran War

The S&P 500 Index ($SPX ) (SPY ) today is up +1.02%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.67%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.10%. June E-mini S&P futures (ESM26 ) are up +1.10%, and June E-mini Nasdaq futures...

Barchart

'Conservatives' want to tax university research. It would kill the goose that lays America's golden eggs

Proposals to levy royalties on university patent licensing threaten to gut the tech-transfer system that spawned Google, Biogen and nearly 20,000 startups.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

What Are Wall Street Analysts' Target Price for Biogen Stock?

Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.

MarketBeat

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

Barchart

What to Expect From Biogen's Next Quarterly Earnings Report

Biogen is expected to announce its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings drop.

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times UK

NHS Refuses to Fund Life-Saving Motor Neurone Disease Medication Despite Free Supply From Drugmaker

MND patients in the UK denied access to lifesaving drug tofersen, despite Biogen supplying it free, due to NHS covering administration costs.

Barchart

MicroStrategy Gets to Stay in the Nasdaq-100. Does It Deserve to Stay in Your Portfolio Too?

MSTR was being eyed for possible Nasdaq-100 removal, but when the index reconstitutes next week, it will get to stay. Other companies, including Biogen and Lululemon, will be removed.

Barchart

Is Biogen Stock Outperforming the Dow?

Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.

Benzinga

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.

Barchart

Biogen Stock: Is Wall Street Bullish or Bearish?

Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Benzinga

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Barchart

What to Expect From Biogen’s Q3 2025 Earnings Report

Biogen is slated to release its fiscal third-quarter earnings later this month, and analysts are expecting its earnings to drop in the single-digit range.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.